logo
welcome
Investor's Business Daily

Investor's Business Daily

AbbVie stock jumps after an analyst upgrades it on the remaining opportunity for its Cerevel takeover

Investor's Business Daily
Summary
Nutrition label

80% Informative

AbbVie 's drug, emraclidine, failed in two final-phase studies of patients with schizophrenia.

Leerink Partners analyst David Risinger says there's still a lot to like about the company.

He says the Cerevel takeover could eventually yield promising drugs in the coming years .

Risinger : "We believe investors can take advantage of the emracridine setback and election-related downdraft to purchase shares in this high-quality company".

VR Score

85

Informative language

92

Neutral language

48

Article tone

formal

Language

English

Language complexity

44

Offensive language

not offensive

Hate speech

not hateful

Attention-grabbing headline

detected

Known propaganda techniques

not detected

Time-value

short-lived

Affiliate links

no affiliate links